HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Hybrid Au@alendronate nanoparticles as dual chemo-photothermal agent for combined cancer treatment

Abstract : A gold therapeutic nanoplatform with the same molecule used as reductant, coating and therapeutic agent has been developed in a one-pot, one-phase process using alendronate, a drug from the bisphosphonate family known for its antitumor effects. In addition, the core made of gold nanoparticles (NPs) brings thermal functionalities under irradiation within the first biological window (650-900 nm). The Au@alendronate nanoplatform thus provided a combined antitumor activity through drug delivery and photothermal therapy. Au@alendronate NPs inhibited in vitro the proliferation of prostate cancer cells (PC3) in a dose-dependent manner, with an IC 50 value of 100 µM. Under NIR irradiation a temperature increase was observed leading to a reduction of the IC 50 value to 1 µM, with total tumor cell death at 100 µM.
Document type :
Journal articles
Complete list of metadata

Cited literature [46 references]  Display  Hide  Download

https://hal.utc.fr/hal-02192626
Contributor : Erwann Guénin Connect in order to contact the contributor
Submitted on : Wednesday, July 24, 2019 - 8:46:21 AM
Last modification on : Sunday, November 28, 2021 - 3:41:33 AM

File

sans-titre.pdf
Publisher files allowed on an open archive

Identifiers

Citation

Anouchka Plan Sangnier, Romain Aufaure, Laurence Motte, Claire Wilhelm, Erwann Guénin, et al.. Hybrid Au@alendronate nanoparticles as dual chemo-photothermal agent for combined cancer treatment. Beilstein Journal of Nanotechnology, Karlsruhe Institute of Technology., 2018, 9, pp.2947-2952. ⟨10.3762/bjnano.9.273⟩. ⟨hal-02192626⟩

Share

Metrics

Record views

70

Files downloads

58